User:Mr. Ibrahem/Orciprenaline
 | |
| Clinical data | |
|---|---|
| Trade names | Alupent, others |
| Other names | Metaproterenol (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682084 |
| Pregnancy category |
|
| Routes of administration | Inhalation (MDI) and tablets |
| Drug class | β2 adrenergic receptor agonist[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 3% inhaled, 40% by mouth |
| Metabolism | Gastrointestinal and liver |
| Elimination half-life | 6 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H17NO3 |
| Molar mass | 211.261 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| Solubility in water | 9.7 mg/mL (20 °C) |
| |
| |
  (what is this?) (verify) | |
Orciprenaline, also known as metaproterenol, is medication used to treat asthma and COPD.[1] It is taken by mouth or inhaled.[1] The medications salbutamol or terbutaline are preferred as they are more effective with less side effects.[2]
Common side effects include anxiety, tremor, headache, palpitations, trouble sleeping, diarrhea, and itchiness.[1] Other side effects may include low potassium and bronchospasm.[1] It is a β2 adrenergic receptor agonist that relaxes smooth muscle in the airways.[1]
Orciprenaline was approved for medical use in the United States in 1973.[1] In the United States 90 tablets of 20 mg costs about 54 USD as of 2021.[3] It was withdrawn from the market in the United Kingdom in 2010.[2]
References[edit]
- ^ a b c d e f g h i "Metaproterenol Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 16 November 2021.
- ^ a b "Orciprenaline sulphate (Alupent): reminder of withdrawal from the market". GOV.UK. Archived from the original on 19 July 2017. Retrieved 17 November 2021.
- ^ "Metaproterenol Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 9 August 2021. Retrieved 17 November 2021.